Leveraging Evolving Data to Inform Treatment in HR-Positive, HER2-Negative Advanced Breast Cancer

Watch the interactive on-demand Webcast and download the slides from a CCO symposium at SABCS 2019 to get up to date on the latest clinical data informing optimal treatment of HR+/HER2- MBC including expert discussion of patient cases and  a look ahead at promising agents in the setting of endocrine therapy&ndash pretreated disease that may soon change practice.

Share

Program Content

No activities added yet

Activities

Future Directions in HR+/HER2- MBC
Novel Therapeutics for HR+/HER2- Metastatic Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2019

Expires: December 09, 2020

PI3K Blockade in HR+/HER2- MBC
Beyond CDK4/6 Inhibition: Putting New Data on Targeting the PI3K Pathway Into Clinical Practice
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2019

Expires: December 09, 2020

CDK4/6i for HR+/HER2- MBC
CDK4/6 Inhibitors in the Management of HR+/HER2- MBC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2019

Expires: December 09, 2020

Faculty

cover img faculity

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

cover img faculity

Eric P. Winer, MD

Director, Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Immunomedics

Lilly